What is Maze Therapeutics, Inc. (MAZE)?

Maze Therapeutics, Inc. (MAZE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of MAZE?

The current price of MAZE is $31.73. Prices are updated in real time on Stocks360.

What is MAZE's price-to-earnings (PE) ratio?

MAZE's trailing twelve-month PE ratio is -11.58, based on current price and earnings per share data available on Stocks360.

What is MAZE's market capitalization?

MAZE's market capitalization is $1,762,575,101.00, placing it in the small-cap tier.

Maze Therapeutics, Inc. (MAZE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$31.73

Market Cap

$1.76B

PE (TTM)

-11.58

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.15

Day Range

$31.24 – $32.08

52-wk Range

$21.95 – $53.65

Avg Volume

N/A

Volume

390.82K

Maze Therapeutics, Inc. (MAZE) is a publicly traded company in the Healthcare sector. Latest price: $31.73. Market cap $1.76B. Trailing PE -11.58. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $31.26 2026-10-28 · $31.73 (+1.50%)

Earnings

Most Recent

Aug 12, 2026

EPS $-0.76 vs est. $-0.72

Missed by $0.04

Next Earnings

Nov 5, 2026

EPS estimate $-0.76

Proprietary Signals

Signal snapshot temporarily unavailable.

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-11.58×
P/S (TTM)	88.13×
P/B	4.13×
PEG	0.22×
P/FCF (TTM)	-16.50×
EV / EBITDA	-12.48×
EV / Sales	81.02×
Earnings Yield	-7.14%
Free Cash Flow Yield	-6.06%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.62B
Revenue (TTM)	$20.00M
Net Income (TTM)	-$125.79M
Free Cash Flow (TTM)	-$105.04M
Net Debt	-$142.22M
Working Capital	$397.46M
Gross Margin	95.28%
Operating Margin	-728.06%
Net Margin	-667.95%
Return on Equity	-34.94%
Return on Invested Capital	-28.35%